Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $662000.0.

  • Kyntra Bio's Share-based Compensation fell 9138.81% to $662000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 8379.11%. This contributed to the annual value of $25.2 million for FY2024, which is 5033.19% down from last year.
  • Per Kyntra Bio's latest filing, its Share-based Compensation stood at $662000.0 for Q3 2025, which was down 9138.81% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Share-based Compensation peaked at $19.4 million during Q1 2021, and registered a low of $178000.0 during Q4 2024.
  • For the 5-year period, Kyntra Bio's Share-based Compensation averaged around $11.5 million, with its median value being $15.6 million (2022).
  • Per our database at Business Quant, Kyntra Bio's Share-based Compensation surged by 1458.97% in 2021 and then crashed by 9808.52% in 2024.
  • Over the past 5 years, Kyntra Bio's Share-based Compensation (Quarter) stood at $17.1 million in 2021, then dropped by 4.97% to $16.2 million in 2022, then plummeted by 42.7% to $9.3 million in 2023, then tumbled by 98.09% to $178000.0 in 2024, then soared by 271.91% to $662000.0 in 2025.
  • Its Share-based Compensation stands at $662000.0 for Q3 2025, versus $1.9 million for Q2 2025 and $2.9 million for Q1 2025.